JP4942906B2 - 卵巣癌の治療および診断のための組成物および方法 - Google Patents

卵巣癌の治療および診断のための組成物および方法 Download PDF

Info

Publication number
JP4942906B2
JP4942906B2 JP2002512217A JP2002512217A JP4942906B2 JP 4942906 B2 JP4942906 B2 JP 4942906B2 JP 2002512217 A JP2002512217 A JP 2002512217A JP 2002512217 A JP2002512217 A JP 2002512217A JP 4942906 B2 JP4942906 B2 JP 4942906B2
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
cells
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002512217A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004526406A (ja
JP2004526406A5 (https=
Inventor
ジェニファー エル． ミッチャム，
ゴードン イー． キング，
ポール エイ． アルゲイト，
スティーブン ピー． フリング，
マーク ダブリュー． レッター，
ギャリー リチャード ファンガー，
スティーブン ジー． リード，
トーマス エス． ヴェドヴィック，
ダリック カーター，
ポール ヒル，
アール アルボーン，
Original Assignee
コリクサ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/636,801 external-priority patent/US7202334B1/en
Priority claimed from US09/667,857 external-priority patent/US6699664B1/en
Priority claimed from US09/827,271 external-priority patent/US6962980B2/en
Priority claimed from US09/884,441 external-priority patent/US20020119158A1/en
Application filed by コリクサ コーポレイション filed Critical コリクサ コーポレイション
Publication of JP2004526406A publication Critical patent/JP2004526406A/ja
Publication of JP2004526406A5 publication Critical patent/JP2004526406A5/ja
Application granted granted Critical
Publication of JP4942906B2 publication Critical patent/JP4942906B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2002512217A 2000-07-17 2001-07-17 卵巣癌の治療および診断のための組成物および方法 Expired - Fee Related JP4942906B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US61774700A 2000-07-17 2000-07-17
US09/617,747 2000-07-17
US09/636,801 US7202334B1 (en) 1998-12-17 2000-08-10 Compositions and methods for the therapy and diagnosis of ovarian cancer
US09/636,801 2000-08-10
US09/667,857 2000-09-20
US09/667,857 US6699664B1 (en) 1998-12-17 2000-09-20 Compositions and methods for the therapy and diagnosis of ovarian cancer
US09/827,271 2001-04-04
US09/827,271 US6962980B2 (en) 1999-09-24 2001-04-04 Compositions and methods for the therapy and diagnosis of ovarian cancer
US09/884,441 2001-06-18
US09/884,441 US20020119158A1 (en) 1998-12-17 2001-06-18 Compositions and methods for the therapy and diagnosis of ovarian cancer
PCT/US2001/022635 WO2002006317A2 (en) 2000-07-17 2001-07-17 Compositions and methods for the therapy and diagnosis of ovarian cancer

Publications (3)

Publication Number Publication Date
JP2004526406A JP2004526406A (ja) 2004-09-02
JP2004526406A5 JP2004526406A5 (https=) 2008-10-02
JP4942906B2 true JP4942906B2 (ja) 2012-05-30

Family

ID=46395398

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002512217A Expired - Fee Related JP4942906B2 (ja) 2000-07-17 2001-07-17 卵巣癌の治療および診断のための組成物および方法

Country Status (3)

Country Link
JP (1) JP4942906B2 (https=)
KR (1) KR100935092B1 (https=)
CY (1) CY1108790T1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202144388A (zh) * 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012758A1 (en) * 1998-09-02 2000-03-09 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating various cancers
WO2000036107A2 (en) * 1998-12-17 2000-06-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012758A1 (en) * 1998-09-02 2000-03-09 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating various cancers
WO2000036107A2 (en) * 1998-12-17 2000-06-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer

Also Published As

Publication number Publication date
KR100935092B1 (ko) 2010-01-08
CY1108790T1 (el) 2014-04-09
JP2004526406A (ja) 2004-09-02
KR20030022293A (ko) 2003-03-15

Similar Documents

Publication Publication Date Title
US6962980B2 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
EP1349870B1 (en) Compositions for the therapy and diagnosis of ovarian cancer
US7202334B1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
EP1183348B1 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
AU2001276973A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002013847A2 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies
CZ20013527A3 (cs) Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
JP2002540790A (ja) 肺癌の治療および診断のための化合物ならびにその使用のための方法
CA2383615A1 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies
JP2010239970A (ja) 乳癌の処置および診断のための組成物ならびにそれらの使用方法
US20020150588A1 (en) SPAS-1 cancer antigen
JP2002540789A5 (https=)
WO2001051513A2 (en) Ovarian tumor-associated sequences
NZ567750A (en) Compositions and uses for cancer therapy
US6933363B1 (en) Compositions and methods for therapy and diagnosis of lung cancer
JP4942906B2 (ja) 卵巣癌の治療および診断のための組成物および方法
ES2350041T3 (es) Composiciones y métodos para la terapia y diagnóstico del cáncer de ovarios.
US20020155468A1 (en) Ovarian tumor antigen and methods of use therefor
WO2002045657A2 (en) Ovarian tumor antigen and methods of use therefor
ES2315296T3 (es) Composiciones para la terapia uy el diagnostico del cancer ovarico.
AU2007216683B2 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
AU2003271300B2 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
US20030157119A1 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies
WO2001027276A2 (en) Dna sequences from breast tumor and uses thereof
KR20010101242A (ko) 난소암의 치료 및 진단용 조성물 및 방법

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20080402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080716

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110719

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120207

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120229

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150309

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees